{
    "nctId": "NCT05234996",
    "briefTitle": "The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patient's Dream Study",
    "officialTitle": "The Immersive Experience of Virtual Reality During Chemotherapy in Patients With Early Breast and Gynecological Cancers: the Patient's Dream Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 44,
    "primaryOutcomeMeasure": "evaluation of Distress",
    "eligibilityCriteria": "Inclusion Criteria\n\n* diagnosis of breast or ovarian cancer confirmed histologically, from I to III stage;\n* surgery as first therapeutic approach (in case of ovarian cancer, patients with minimal residual disease after surgery will be also included)\n* first cycle of adjuvant CT, with or without a biological treatment according to the specific cancer (regimens including anthracyclines/taxanes, anthracyclines/cyclophosphamide, carboplatinum/taxane combined or not with trastuzumab for breast cancer, carboplatin/paclitaxel combined or not with bevacizumab for ovarian cancer);\n* aged \u2265 18 years;\n* performance status (ECOG) 0-2;\n* life expectancy \\> 12 months;\n* ability to understand and sign the informed consent.\n\nExclusion Criteria:\n\n* presenting prior history of seizures;\n* disorders of the mood;\n* previous history of alcohol and/or drug addiction;\n* disorder of vision and eyes;\n* history of psychiatric pathologies.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}